A Year-End Buyer's Guide to Modern Consultant-Pharmacy Software

Short answer: to evaluate consultant-pharmacy software well, start with your own practice rather than a vendor demo. Map the full medication regimen review workflow from context gathering to prescriber follow-up, test how much control the pharmacist keeps over AI-assisted recommendations, separate what a vendor ships today from what is on the roadmap, understand which category each competitor actually sits in, and define what a transition requires before go-live. Year-end is a good moment to run that exercise because budget planning and renewal cycles line up with it.

For many consultant-pharmacy practices, medication regimen review software is not a casual purchase. It holds a recurring clinical and operating process, often one the organization has used for years. A credible evaluation of an alternative should therefore begin with the practice, not the product pitch.

Why year-end is the right moment to evaluate

Budget planning and contract renewal cycles commonly fall at year-end for long-term care pharmacy practices. That timing creates a decision window, and it also creates pressure.

A switch made under renewal pressure tends to skip the analysis that actually predicts success. The buyer looks at screens, likes or dislikes them, and signs or renews. The surrounding work, the handoffs, the reporting and the historical data never get examined.

Starting the mapping exercise early leaves room for a structured evaluation instead of a forced decision. You are then comparing your current tool against your own written requirements, not against a demo agenda set by whoever called you first.

Map the full medication regimen review workflow, not just the review screen

The review screen is the visible part of the job. It is rarely where most of the time goes.

Document what happens before the review. How are medication administration records, physician orders, diagnoses and lab values assembled into a usable clinical picture? Who does that assembly, and how long does it take per resident?

Document what happens during the review. How does an identified issue become a written recommendation? What clinical reasoning and evidence are attached to it? What does the pharmacist have to retype or restate that the system already knows?

Document what happens after the review. How are recommendations communicated to the facility and to prescribers? How are responses captured? What is documented for the record, and in what format?

Finally, document what carries forward. Which open recommendations, unresolved issues and handoff notes need to be visible at the start of the next cycle, and to a different pharmacist covering the same building?

A tool that only speeds up the visible review step can leave the rest of the work fragmented across spreadsheets, email and paper. In our experience that fragmentation is where the hidden hours live.

Test how much control the pharmacist actually keeps

Any product using AI in clinical decision support should be able to answer one question plainly: what can the pharmacist inspect, modify, reject and finalize?

Ask to see a generated recommendation opened for review. Look for the ability to read the reasoning behind it, see the medications and clinical context it was drawn from, edit the wording, change the category, reject it outright and approve only what belongs in the final record.

In Pharmacore, generated recommendations land in a review step where they are grouped by category and filtered before anything is finalized, and the same review surface can be opened in a detached window so the pharmacist can work through recommendations alongside the resident chart. Nothing reaches a facility or a prescriber without a pharmacist approving it.

That distinction matters more than any feature list. Decision support should organize clinical reasoning and surface relevant evidence. It should not convert a suggestion into an autonomous conclusion. The final recommendation is the pharmacist's professional judgment and the pharmacist's signature.

If a vendor cannot show you the editable review step, assume it does not exist.

Separate what a vendor offers today from what is on the roadmap

Demos blur tenses. A feature described in the present tense may be shipping, in active development or a slide.

Require every capability discussed to carry one of three labels: available now, in active development, or planned with no committed date. Ask for that labeling in writing after the call, and ask to see the "available now" items running on real data rather than a static screenshot.

Evaluate your current requirements against the current product only. A roadmap tells you where a vendor intends to go and how they think about the category, which is useful context for a multi-year relationship. It is not proof that a feature exists at demo time, and it should not carry weight in a scoring matrix.

Know the landscape before you compare like-for-like

Buyers often put very different kinds of products on the same comparison sheet. Sorting them into categories first saves a lot of wasted evaluation time.

Legacy MRR platforms

The established consultant pharmacy review category dates back to the 1990s, with RxPertise built in 1996, and the underlying platform approach has changed little since. Many practices still run reviews in desktop-era software supplemented by spreadsheets and paper. That is the baseline most alternatives are measured against.

Review tools bundled with a dispensing system

FrameworkRxP from SoftWriters is a cloud review layer built on top of the FrameworkLTC dispensing system, using real-time dispensing data, handoff notes and multi-facility reporting. Bundling has genuine advantages when your pharmacy is already on that dispensing platform. It also couples your review tool to your dispensing vendor and excludes pharmacies running anything else.

EHR systems of record

PointClickCare and MatrixCare are the dominant long-term and post-acute care EHRs, with eMAR and pharmacy integrations. They are the system of record that a review workflow draws from, not a consultant pharmacist review product. Comparing an EHR to an MRR platform is a category error.

Internal programs at large LTC pharmacy providers

Omnicare uses proprietary internal decision support known as OSC2OR to flag issues such as antipsychotic and antibiotic overuse. PharMerica and Guardian Pharmacy Services run their own consultant pharmacist programs. None of these are sold to independent pharmacies as software, so they function as service competitors rather than products you can buy.

Platform-independent review software

A review platform that is not tied to a single dispensing system or EHR vendor can serve a pharmacy regardless of which systems its facilities run. That independence is the practical question to ask if you work across buildings on different platforms, or if you want your review tool and your dispensing contract to be separable decisions. Pharmacore is built to be independent of any one dispensing system or EHR.

Define what a transition actually requires

Changing systems is an operational project, not a software install. Write the list before you sign anything.

• The reports your practice, your facilities and your surveyors expect, in the formats they expect them.
• Historical recommendation data, including how far back you need it and whether it must be searchable or only archived.
• Facility and resident records, including how new residents and admissions flow in.
• User roles and permissions, including per-facility access and coverage arrangements.
• Handoff processes between pharmacists, and between the pharmacy and each facility.
• Prescriber communication paths and the documentation trail behind them.

Then confirm, item by item, that the new platform or an agreed transition plan accounts for each one before go-live. A modern interface does not remove the operational responsibility of migrating a running clinical process.

Agree on the evidence your team needs before the demo

Decide up front what your team needs to observe. Reasonable criteria include workflow fit against the map you built, day-to-day usability for the pharmacists who will live in the tool, reviewability of AI-generated recommendations, reporting that matches what facilities ask for, and continuity across review cycles and across covering pharmacists.

Write those criteria down and use the same ones in every vendor conversation. Avoid asking vendors for performance claims your evaluation was never designed to measure. A number nobody can verify is worse than no number, because it displaces the criteria you can actually test.

Choose a clear next step after the demo

A strong demonstration should end in one of three honest outcomes: proceed to a structured evaluation, name a specific requirement that must be resolved first, or conclude that the timing or fit is not right.

Clarity at this stage serves both sides better than an indefinite follow-up sequence. If a vendor will not accept "not now" as an answer, that tells you something about how they will behave as a partner.

Bring this checklist into your next vendor conversation. If you would like to work through it with us, you can book a Pharmacore evaluation-mapping session, browse the Pharmacore resources library, or see how our clinical intelligence for long-term care, decision support for consultant pharmacists fits the workflow you just mapped. We will also be at ASCP 2026 if you would rather have the conversation in person.

Frequently asked questions

What is the best time of year to evaluate consultant-pharmacy software?

Year-end lines up with budget planning and contract renewal cycles for many long-term care pharmacy practices. Starting a workflow-mapping exercise before renewal deadlines gives your team time to compare current tools against written requirements, rather than deciding on the incumbent's timeline.

How is AI clinical decision support different from an automated decision?

Decision support organizes clinical reasoning, surfaces relevant context and suggests recommendations for review. The pharmacist inspects, edits, rejects or finalizes each one. The final recommendation remains the pharmacist's professional judgment, not an automated output.

Do I need to be on a specific dispensing system or EHR to use a modern MRR platform?

Not necessarily. Some review tools, such as FrameworkRxP, are built on top of a specific dispensing system, FrameworkLTC, and are available only to pharmacies using it. A platform-independent tool is not tied to a particular dispensing system or EHR vendor, which matters if your pharmacy uses a different system or covers facilities on different platforms.

What should I ask about a vendor's product roadmap during evaluation?

Ask the vendor to label each capability as available now, in active development, or planned with no committed date. Evaluate your current requirements against what is available today, and treat roadmap items as direction for the relationship rather than proof that a feature exists.

What data and workflow details do I need before switching systems?

Compile the reports, historical recommendation data, facility and resident records, user roles and permissions, and handoff processes your practice depends on today. Then confirm that the new platform, or your transition plan, accounts for each one before go-live.

Who are the other players in the LTC consultant-pharmacy and MRR space?

Large long-term care pharmacy providers such as PharMerica and Guardian Pharmacy Services run their own consultant pharmacist programs. EHR platforms such as PointClickCare and MatrixCare provide the system of record with pharmacy integrations. Omnicare uses internal decision support called OSC2OR that is not sold externally. None of these is a like-for-like substitute for a standalone MRR review platform, so be clear about which category you are comparing against.